Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer
The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or co...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1260818/full |
| _version_ | 1797665675827740672 |
|---|---|
| author | Hirofumi Ohmura Moe Kondo Masato Uenomachi Hiroshi Ariyama Mamoru Ito Kenji Tsuchihashi Masahiro Ayano Hiroaki Niiro Koichi Akashi Eishi Baba |
| author_facet | Hirofumi Ohmura Moe Kondo Masato Uenomachi Hiroshi Ariyama Mamoru Ito Kenji Tsuchihashi Masahiro Ayano Hiroaki Niiro Koichi Akashi Eishi Baba |
| author_sort | Hirofumi Ohmura |
| collection | DOAJ |
| description | The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or conventional molecular-targeted drugs including tyrosine kinase inhibitors, have been reported. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare autoimmune disorder with acute-onset, rheumatoid factor-negative, symmetric synovitis associated with limb edema observed in elderly persons. A case of RS3PE syndrome that developed after administration of nivolumab for advanced gastric cancer is reported. This is the first report of a case of RS3PE syndrome as an irAE caused by nivolumab in a patient with gastric cancer. |
| first_indexed | 2024-03-11T19:48:29Z |
| format | Article |
| id | doaj.art-64ec702a8066473396e5b1fb9e89851f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T19:48:29Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-64ec702a8066473396e5b1fb9e89851f2023-10-05T19:23:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12608181260818Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancerHirofumi Ohmura0Moe Kondo1Masato Uenomachi2Hiroshi Ariyama3Mamoru Ito4Kenji Tsuchihashi5Masahiro Ayano6Hiroaki Niiro7Koichi Akashi8Eishi Baba9Department of Oncology and Social Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Diabetes Mellitus and Endocrinology, Nanpuh Hospital, Kagoshima, JapanDepartment of Oncology, Kitakyushu Municipal Medical Center, Fukuoka, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Medical Education, Kyushu University Faculty of Medical Sciences, Fukuoka, JapanDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanDepartment of Oncology and Social Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, JapanThe anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or conventional molecular-targeted drugs including tyrosine kinase inhibitors, have been reported. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare autoimmune disorder with acute-onset, rheumatoid factor-negative, symmetric synovitis associated with limb edema observed in elderly persons. A case of RS3PE syndrome that developed after administration of nivolumab for advanced gastric cancer is reported. This is the first report of a case of RS3PE syndrome as an irAE caused by nivolumab in a patient with gastric cancer.https://www.frontiersin.org/articles/10.3389/fonc.2023.1260818/fullgastric cancerRS3PEirAEnivolumabpathology |
| spellingShingle | Hirofumi Ohmura Moe Kondo Masato Uenomachi Hiroshi Ariyama Mamoru Ito Kenji Tsuchihashi Masahiro Ayano Hiroaki Niiro Koichi Akashi Eishi Baba Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer Frontiers in Oncology gastric cancer RS3PE irAE nivolumab pathology |
| title | Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| title_full | Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| title_fullStr | Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| title_full_unstemmed | Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| title_short | Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| title_sort | case report resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer |
| topic | gastric cancer RS3PE irAE nivolumab pathology |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1260818/full |
| work_keys_str_mv | AT hirofumiohmura casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT moekondo casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT masatouenomachi casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT hiroshiariyama casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT mamoruito casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT kenjitsuchihashi casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT masahiroayano casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT hiroakiniiro casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT koichiakashi casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer AT eishibaba casereportresolutionofremittingseronegativesymmetricalsynovitiswithpittingedemaduringnivolumabtherapyforgastriccancer |